Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05759468 · ClinicalTrials.gov registry record · Phase 2
NAD Augmentation in Diabetes Kidney Disease
A Phase 2 study of Diabetic Kidney Disease and Type2diabetes, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT05759468 is a Phase 2 study of Diabetic Kidney Disease and Type2diabetes that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 140 participants, below the 5,184-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05759468, a Phase 2 study of Diabetic Kidney Disease and Type2diabetes, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Investigational Product - MIB 626
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2023-04-13 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05759468
The ClinicalTrials.gov registry entry for NCT05759468 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,184-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (97% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05759468 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05759468 about?
NCT05759468 is a clinical study titled "NAD Augmentation in Diabetes Kidney Disease". A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg...
What is the current status of trial NCT05759468?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2023-04-13. Estimated completion is 2027-03-31.
What conditions does trial NCT05759468 study?
This clinical trial studies the following conditions: Diabetic Kidney Disease, Type2diabetes.
What interventions are being tested in trial NCT05759468?
The interventions under investigation include: Placebo (DRUG), Investigational Product - MIB 626 (DRUG).
Who is sponsoring clinical trial NCT05759468?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05759468 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Formoterol in Diabetes
RECRUITING · Phase 2
-
Renal Mechanism of SGLT2 Inhibition
RECRUITING · Phase 2
-
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
RECRUITING · Phase 2
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Coffee Therapy for Improvement of Renal Oxygenation
COMPLETED · Phase 2
-
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.